公开(公告)号：US20180280474A1

公开(公告)日：2018-10-04

申请号：US15765144

申请日：2016-09-30

Applicant: AMGEN INC.

Inventor： Jing Xu ,  Shanaka Stanislaus ,  Mei-Hsiu M. Chen ,  Clarence H. Hale ,  Murielle Veniant-Ellison

IPC: A61K38/18 ,  A61P1/00 ,  A61P1/16

Abstract: The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.

公开(公告)号：US09714276B2

公开(公告)日：2017-07-25

申请号：US14374885

申请日：2013-01-28

Applicant: AMGEN INC

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Zeqi Sheng ,  Agnes Eva Hamburger ,  Murielle Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Bryan Lemon

IPC: C07K14/00 ,  C07K14/475 ,  A61K39/00 ,  C12N15/62

CPC classification number: C07K14/475 ,  A61K39/0005 ,  A61K2039/6056 ,  C07K2319/30

Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US09862752B2

公开(公告)日：2018-01-09

申请号：US14908459

申请日：2014-07-31

Applicant: Amgen Inc.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Z. Sheng ,  Agnes Eva Hamburger ,  Murielle Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Marissa Mock ,  Kenneth Walker

IPC: C07K14/00 ,  C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20140378665A1

公开(公告)日：2014-12-25

申请号：US14374885

申请日：2013-01-28

Applicant: AMGEN INC.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Zeqi Sheng ,  Agnes Eva Hamburger ,  Murielle Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Bryan Lemon

IPC: C07K14/475

CPC classification number: C07K14/475 ,  A61K39/0005 ,  A61K2039/6056 ,  C07K2319/30

Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Abstract translation: 提供GDF15多肽，包含GDF15的构建体及其突变体。 在各种实施方案中，GDF15多肽，包含GDF15的构建体及其突变体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。